U.S. Alzheimers Disease Biomarkers Market Insight
U.S. Alzheimers Disease Biomarkers market size is growing at a 14.69% CAGR, driven by Rising Alzheimer’s prevalence, demand for early diagnosis, advancements in blood-based biomarkers, increasing R&D investments
U.S. Alzheimers Disease Biomarkers Market Insights Forecasts to 2035
- The U.S. Alzheimers Disease Biomarkers Market Size Was Estimated at USD 66.81 Million in 2025.
- The Market Size is Expected to Grow at a CAGR of around 14.69% from 2025 to 2035.
- The U.S. Alzheimers Disease Biomarkers Market Size is Expected to Reach USD 263.15 Million by 2035.
Notable Insights for U.S. Alzheimers Disease Biomarkers Market
- Tau-related biomarkers dominated the market, accounting for approximately 37.08% share in 2024, driven by strong clinical accuracy in early Alzheimer’s detection.
- Hospitals dominated end-use in 2024, as primary centers for biomarker testing due to advanced diagnostic infrastructure and integration into clinical workflows. The FDA approval of blood-based Alzheimer’s diagnostic tests in 2025 significantly accelerated clinical adoption, reducing reliance on invasive PET scans and lumbar punctures. Additionally, the increasing expansion of biomarker testing into clinical labs, community hospitals, and memory care centers is enhancing accessibility and driving nationwide market penetration.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the U.S. Alzheimers Disease Biomarkers market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in U.S. Alzheimers Disease Biomarkers Market
- F. Hoffmann-La Roche Ltd
- Quanterix Corporation
- Fujirebio
- C2N Diagnostics
- Labcorp
- Quest Diagnostics Incorporated
- Siemens Healthineers
- Abbott Laboratories
- BioArctic AB
- Diadem srl
- Others
Recent Developments:
- In May 2025, the United States FDA approved the first blood-based Alzheimer’s diagnostic test (Lumipulse), enabling detection of amyloid biomarkers through a simple blood draw, significantly improving early diagnosis accessibility.
- In October 2025, the United States approved Roche’s Elecsys pTau181 blood test, achieving around 97.9% negative predictive value, expanding biomarker testing into primary care and accelerating clinical adoption.
- In April 2026, researchers introduced a next-generation blood biomarker test predicting Alzheimer’s progression, analyzing markers like p-tau217 and neurofilament light chain, improving disease monitoring and treatment planning.
Market Segmentation:
U.S. Alzheimers Disease Biomarkers Market, By Service Solution
• Amyloid-related Biomarkers
• Tau-related Biomarkers
• Neurodegeneration Biomarkers
• Others
U.S. Alzheimers Disease Biomarkers Market, By Technology
• Immunoassays (ELISA, CLIA, Simoa)
• Mass Spectrometry
• Molecular Diagnostics
• Next-Generation Platforms
U.S. Alzheimers Disease Biomarkers Market, By Application
• Early Diagnosis and Screening
• Disease Monitoring
• Drug Development and Clinical Trials
• Risk Assessment
U.S. Alzheimers Disease Biomarkers Market, By Sample Type
• Blood-Based Biomarkers
• Cerebrospinal Fluid (CSF) Biomarkers
• Imaging Biomarkers (PET, MRI)
Expert Views:
Industry experts emphasize that the U.S. Alzheimer’s disease biomarkers market is undergoing rapid transformation driven by the shift toward early and non-invasive diagnosis, particularly through blood-based testing. Researchers and clinicians highlight that biomarkers such as amyloid-beta and phosphorylated tau (p-tau217, p-tau181) are becoming essential tools for identifying Alzheimer’s at pre-symptomatic stages, enabling timely intervention and improved patient outcomes. Experts from diagnostics and biotechnology companies note that ultra-sensitive detection technologies like Simoa and mass spectrometry are significantly enhancing accuracy and scalability, allowing biomarker tests to move from research settings into routine clinical practice.